Ranexa Approved - CV Therapeutics, Inc. - Treatment for Chronic Angina
Ranexa is a novel antianginal and anti-ischemic agent indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs.Posted: January 2006
Related articles
- FDA Approves Ranexa for First Line Anti Anginal Use - November 6, 2008
- FDA Approves New Mechanism of Action Labeling for Ranexa - December 19, 2007
- CV Therapeutics Launches 1000 mg Ranexa Tablet - August 14, 2007
- CV Therapeutics Submits Amendment to Ranexa (ranolazine) - July 27, 2005
Ranexa (ranolazine) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
